Three of the fifteen cases with the BRCA1/2 mutations reported invasive cancer in the ipsilateral or the contralateral breast, diagnosed, on average, 6 years from the date of DCIS diagnosis. This evidence concerns the gene BRCA1 and ductal breast carcinoma in situ.